Revolver Therapeutics develops peptide therapeutics using a screening platform to target transcription factors for cancer treatment.
Revolver Therapeutics has raised $764K in total funding. The most recent round was Pre-Seed. The last funding was announced in July 2026.
Revolver Therapeutics's investors include University of Bath, UK Innovation & Science Seed Fund, QantX, O2h Ventures.
Revolver Therapeutics is headquartered in Bath, United Kingdom.
Revolver Therapeutics develops peptide therapeutics using a screening platform to target transcription factors for cancer treatment.
Revolver Therapeutics is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Revolver Therapeutics — Funding & Investors." VCBacked, July 3, 2026, https://www.vcbacked.co/company/revolver-therapeutics. Accessed August 1, 2026.
VCBacked. (2026). Revolver Therapeutics — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/revolver-therapeutics
{{cite web |title=Revolver Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/revolver-therapeutics |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated